InsidersTradesSigma
Total declarations
Company
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
6
Disclosed sells
0
T+90 hit rate
25%
T+90 mean return
-8.0%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Vitt Daniel, Chief Executive Officer. Officer active across 1 company, notably Immunic, INC.. Aggregated, 6 reports have been logged. Split: 6 buys · 0 sell. Total volume traded: €70k. Activity tracked since 10 August 2021. The latest transaction was filed on 4 June 2025 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Vitt Daniel
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
15,000 shares@ US$0.7714.4% of flowCommon StockSEC:0001193805-25-000923:0
Canonical exit: 2 Sept 2025 (T+90)
15,000 shares@ US$0.7716.8% of flowCommon StockSEC:0001193805-25-000821:0
Canonical exit: 2 Sept 2025 (T+90)
14,000 shares@ US$1.309529.1% of flowCommon StockSEC:0001193805-24-000282:0
Canonical exit: 26 May 2024 (T+90)
8,000 shares@ US$1.349918.1% of flowCommon StockSEC:0001193805-22-001602:0
Canonical exit: 20 Feb 2023 (T+90)
5,000 shares@ US$3.099923.9% of flowCommon StockSEC:0001193805-22-000919:0
Canonical exit: 1 Sept 2022 (T+90)
1,000 shares@ US$9.6013.6% of flowCommon StockSEC:0001193805-21-001161:0
Canonical exit: 8 Nov 2021 (T+90)
6 of 6 declarations
About Vitt Daniel
Daniel Vitt is the President and CEO of Immunic, Inc. He leads the strategic and business operations of the company, focusing on innovation in the biotechnology sector. His leadership is essential in guiding the company's vision and growth.
